Spontaneous Muscle Hematoma in Japanese Patients with Severe COVID-19 Treated with Unfractionated Heparin : Two Case Reports
In hospitalized coronavirus disease 2019 (COVID-19) patients, anticoagulation therapy is administered to prevent thrombosis. However, anticoagulation sometimes causes bleeding complications. We herein report two Japanese cases of severe COVID-19 in which spontaneous muscle hematomas (SMH) developed under therapeutic anticoagulation with unfractionated heparin. Although the activated partial prothrombin time was within the optimal range, contrast-enhanced computed tomography (CECT) revealed SMH in the bilateral iliopsoas muscles in both cases, which required emergent transcatheter embolization. Close monitoring of the coagulation system and the early diagnosis of bleeding complications through CECT are needed in severe COVID-19 patients treated with anticoagulants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - 60(2021), 21 vom: 01. Nov., Seite 3503-3506 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ito, Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9005-49-6 |
|---|
| Anmerkungen: |
Date Completed 02.11.2021 Date Revised 11.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2169/internalmedicine.7422-21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329768751 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329768751 | ||
| 003 | DE-627 | ||
| 005 | 20231225205836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.7422-21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329768751 | ||
| 035 | |a (NLM)34433713 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ito, Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spontaneous Muscle Hematoma in Japanese Patients with Severe COVID-19 Treated with Unfractionated Heparin |b Two Case Reports |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2021 | ||
| 500 | |a Date Revised 11.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In hospitalized coronavirus disease 2019 (COVID-19) patients, anticoagulation therapy is administered to prevent thrombosis. However, anticoagulation sometimes causes bleeding complications. We herein report two Japanese cases of severe COVID-19 in which spontaneous muscle hematomas (SMH) developed under therapeutic anticoagulation with unfractionated heparin. Although the activated partial prothrombin time was within the optimal range, contrast-enhanced computed tomography (CECT) revealed SMH in the bilateral iliopsoas muscles in both cases, which required emergent transcatheter embolization. Close monitoring of the coagulation system and the early diagnosis of bleeding complications through CECT are needed in severe COVID-19 patients treated with anticoagulants | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a spontaneous muscle hematoma | |
| 650 | 4 | |a therapeutic anticoagulation | |
| 650 | 4 | |a unfractionated heparin | |
| 650 | 4 | |a vascular dysfunction | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Heparin |2 NLM | |
| 650 | 7 | |a 9005-49-6 |2 NLM | |
| 700 | 1 | |a Awano, Nobuyasu |e verfasserin |4 aut | |
| 700 | 1 | |a Uchiyama, Fumiya |e verfasserin |4 aut | |
| 700 | 1 | |a Inomata, Minoru |e verfasserin |4 aut | |
| 700 | 1 | |a Kuse, Naoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Tone, Mari |e verfasserin |4 aut | |
| 700 | 1 | |a Takada, Kohei |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimoto, Kazushi |e verfasserin |4 aut | |
| 700 | 1 | |a Muto, Yutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Sagisaka, Shogo |e verfasserin |4 aut | |
| 700 | 1 | |a Maki, Kenro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamashita, Ryuta |e verfasserin |4 aut | |
| 700 | 1 | |a Harada, Akinori |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Jun-Ichi |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Munehiro |e verfasserin |4 aut | |
| 700 | 1 | |a Izumo, Takehiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g 60(2021), 21 vom: 01. Nov., Seite 3503-3506 |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2021 |g number:21 |g day:01 |g month:11 |g pages:3503-3506 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.7422-21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2021 |e 21 |b 01 |c 11 |h 3503-3506 | ||